Trade

with

Antares Pharma Inc
(NASDAQ: ATRS)
AdChoices
2.03
+0.02
+1.00%
After Hours :
2.03
0.00
0.00%

Open

2.00

Previous Close

2.01

Volume (Avg)

465.90k (1.09M)

Day's Range

1.95-2.04

52Wk Range

1.82-5.01

Market Cap.

264.85M

Dividend Rate ( Yield )

-

Beta

0.42

Shares Outstanding

130.47M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Medical Instruments & Supplies
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 20.62M

    • Net Income

    • -20.51M

    • Market Cap.

    • 264.85M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -137.21

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.42

    • Forward P/E

    • 50.76

    • Price/Sales

    • 11.99

    • Price/Book Value

    • 4.78

    • Price/Cash flow

    • -13.46

      • EBITDA

      • -20.29M

      • Return on Capital %

      • -34.69

      • Return on Equity %

      • -44.32

      • Return on Assets %

      • -34.69

      • Book Value/Share

      • 0.42

      • Shares Outstanding

      • 130.47M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 4.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 0.04

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 8.40

          • 10.42

          • Net Income

            YTD/YTD (last year)

          • -

          • -15.59

          • Net Income

            Q/Q (last year)

          • -

          • -8.93

          • Sales (Revenue)

            5-Year Annual Average

          • 29.50

          • 12.51

          • Net Income

            5-Year Annual Average

          • -

          • 4.16

          • Dividends

            5-Year Annual Average

          • -

          • 0.97

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 67.88

            • 52.83

            • Pre-Tax Margin

            • -138.59

            • 15.96

            • Net Profit Margin

            • -137.21

            • 12.40

            • Average Gross Margin

              5-Year Annual Average

            • 57.80

            • 52.66

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 18.40

            • Average Net Profit Margin

              5-Year Annual Average

            • -69.60

            • 93.46B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.62

              • Current Ratio

              • 3.13

              • 1.97

              • Quick Ratio

              • 2.66

              • 1.16

              • Interest Coverage

              • -

              • 10.47

              • Leverage Ratio

              • 1.49

              • 2.38

              • Book Value/Share

              • 0.42

              • 12.15

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.74

                • 36.10

                • P/E Ratio 5-Year High

                • -24.03

                • 279.08

                • P/E Ratio 5-Year Low

                • -4.35

                • 148.87

                • Price/Sales Ratio

                • 11.99

                • 3.37

                • Price/Book Value

                • 4.78

                • 4.21

                • Price/Cash Flow Ratio

                • -13.46

                • 17.42

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -44.32

                        (-55.10)

                      • 17.93

                        (21.42)

                      • Return on Assets %

                        (5-Year Average)

                      • -34.69

                        (-28.50)

                      • 7.35

                        (9.50)

                      • Return on Capital %

                        (5-Year Average)

                      • -44.32

                        (-50.30)

                      • 10.24

                        (13.59)

                      • Income/Employee

                      • -

                      • 25.65k

                      • Inventory Turnover

                      • 1.49

                      • 2.66

                      • Asset Turnover

                      • 0.25

                      • 0.59

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -20.85M
                      Operating Margin
                      -101.12
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -13.46
                      Ownership

                      Institutional Ownership

                      33.83%

                      Top 10 Institutions

                      24.94%

                      Mutual Fund Ownership

                      9.45%

                      Float

                      89.77%

                      5% / Insider Ownership

                      9.68%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,912,926

                      • 2.57

                      • 1.47

                      • iShares Russell 2000 (AU)

                      •  

                        1,766,916

                      • -1.46

                      • 1.49

                      • Vanguard Extended Market Index Fund

                      •  

                        1,295,076

                      • 0.44

                      • 0.99

                      • iShares Russell 2000 Growth

                      •  

                        844,070

                      • 0.34

                      • 0.71

                      • Putnam Global Health Care Fund

                      •  

                        650,400

                      • 0.00

                      • 0.50

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        441,109

                      • 0.00

                      • 0.34

                      • UBS U.S. Small Capitalization Growth Fun

                      •  

                        400,000

                      • 0.00

                      • 0.31

                      • CREF Stock

                      •  

                        364,671

                      • 0.00

                      • 0.28

                      • iShares Micro-Cap

                      •  

                        293,377

                      • 0.00

                      • 0.25

                      • Vanguard Instl Total Stock Market Index

                      •  

                        258,527

                      • 0.00

                      • 0.20

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Deerfield Management Co

                      •  

                        9,603,703

                      • +1.21%

                      • 7.37

                      • Millennium Management LLC

                      •  

                        4,067,481

                      • +81.05%

                      • 3.12

                      • BlackRock Fund Advisors

                      •  

                        3,995,423

                      • -1.70%

                      • 3.07

                      • Vanguard Group, Inc.

                      •  

                        3,875,750

                      • +2.79%

                      • 2.97

                      • Broadfin Capital, LLC

                      •  

                        3,050,000

                      • +32.61%

                      • 2.34

                      • Harris William Investors Inc

                      •  

                        2,338,735

                      • +54.50%

                      • 1.79

                      • State Street Corp

                      •  

                        2,003,165

                      • -0.01%

                      • 1.54

                      • Northern Trust Investments, N.A.

                      •  

                        1,313,397

                      • -10.53%

                      • 1.01

                      • Kingdon Capital Management LLC

                      •  

                        1,165,738

                      • -21.80%

                      • 0.89

                      • Ashford Capital Management Inc

                      •  

                        1,088,675

                      • +26.51%

                      • 0.84

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Medical Instruments & Supplies

                      Type

                      Distressed

                      Style

                      Small Growth

                      Antares Pharma, Inc., formerly known as Medi-Ject Corporation, or Medi-Ject, was incorporated on February 1979. The Company is a specialty pharmaceutical company developing and commercializing self-administered parenteral pharmaceuti...morecal products and technologies. It has a number of partnerships with pharmaceutical companies as well as internal product development programs. It develops both subcutaneous and intramuscular injection technology systems. It launched OTREXUP injection on January 2014, is a subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. It is indicated for adults with severe active rheumatoid arthritis or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. ...moreThe Company has international marketing rights for its OTREXUP. It is also developing Vibex QS for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency. The Company has licensed its reusable needle-free injection device for use with human growth hormone to Teva Pharmaceutical Industries, Ltd., Ferring Pharmaceuticals BV and JCR Pharmaceuticals Co., Ltd., with Teva and Ferring being two of the Company's primary customers. The Company's needle-free injection device is marketed by Teva as the Tjet injector system to administer their 5mg Tev-Tropin brand hGH marketed in the U.S. The Company's needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet 2 Vision and Zomajet Vision X, respectively, in Europe and Asia. It has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. It also has a portfolio of gel-based products such as Gelnique, a topical oxybutynin gel product for the treatment of overactive bladder. Gelnique is marketed by Actavis in the U.S. In South Korea, Gelnique is marketed by Daewoong Pharmaceuticals. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, among others.lessless

                      Key People

                      Eamonn P. Hobbs

                      Director/President/CEO

                      Dr. Leonard S. Jacob,M.D.,PhD

                      Chairman of the Board/Director

                      Robert F. Apple

                      COO/CFO/Chief Accounting Officer/Executive VP

                      Jack Howarth

                      Vice President, Divisional

                      Anton G. Gueth

                      Director

                      • Antares Pharma Inc

                      • 100 Princeton South

                      • Ewing, NJ 08628

                      • USA.Map

                      • Phone: +1 609 359-3020

                      • Fax: -

                      • antarespharma.com

                      Incorporated

                      1979

                      Employees

                      60

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: